Elzonris

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).[3][4] It was approved for use in the United States in 2018,[5] and after a second review, in the EU in January 2021.[2] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6] Tagraxofusp is a fusion protein consisting of i... [wikipedia]